[en] •Efficacy of new treatments in SMA is better in pre than in post-symptomatic patients
•NBS is complementary of carriers screening, with different false negatives
•Pilot projects of SMA NBS have started or are planned to start in several countries
•Questions remain on SMN2 quantification and management of patients with 4 copies
•We propose a strategy to launch an evidence-based approach for these patients
Disciplines :
Neurology
Author, co-author :
Dangouloff, Tamara ; Université de Liège - ULiège > Département des sciences cliniques > Neuropédiatrie
Burghes, Arthur; Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH, USA
BOEMER, François ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire Biochimie Génétique
Hiligsmann, Mickaël ; Maastricht University, The Netherlands > Département des sciences de la santé publique > CAPHRI Care and Public Health Research Institute
Mueller-Felber, Wolfgang; Dr. v. Hauner Children's Hospital, Ludwig-Maximilian University of Munich, Munich, Germany
Tiziano, Franceso Danilo; Catholic University of sacred Heart, Rome, Italy
Young, Philip; School of Life Sciences, University of Warwick, Coventry, UK
Germanenko, Olga; Patient Advocacy Group, SMA Family Russia
De Lemus, Mencia; Patient Advocacy Group, FundAME and SMA Europe
Rucinski, Kacper; Patient Advocacy Group, SMA Foundation Poland
Stephenson, Kristin; Muscular Dystrophy Association, Washington, DC, USA
Farwell, Wildon; Biogen, Boston, MA, USA
Gorni, Ksenija; F. Hoffmann-La Roche Ltd - Roche
Hjort, Mikael; PerkinElmer Finland
Kausar, Imran; Avexis, Novartis, Bannockburn , USA
Tizzano, Eduardo F; Department of Clinical and Molecular Genetics, University Hospital Valle Hebron, Medicine Genetics Group VHIR, Pso. Vall d’ Hebron, Barcelona, Spain
Servais, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Identification and characterization of a spinal muscular atrophy-determining gene (1995) Cell, 80 (1), pp. 155-165
Alias, L., Bernal, S., Fuentes-Prior, P., Barcelo, M.J., Also, E., Martinez-Hernandez, R., Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene (2009) Hum genet., 125 (1), pp. 29-39
Dubowitz, V., Sixty years of spinal muscular atrophy: a personal odyssey (2017) Spinal muscular atrophy, , C.J. Sumner S. Paushkin Ko C.-P. Academic Press xvii–xxxi
Klug, C., Schreiber-Katz, O., Thiele, S., Schorling, E., Zowe, J., Reilich, P., Disease burden of spinal muscular atrophy in Germany (2016) Orphanet J Rare Dis., 11 (1), p. 58
Chabanon, A., Seferian, A.M., Daron, A., Pereon, Y., Cances, C., Vuillerot, C., Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data Nathis-Sma study (2018) PLoS ONE, 13 (7)
Calucho, M., Bernal, S., Alias, L., March, F., Vencesla, A., Rodriguez-Alvarez, F.J., Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated spanish patients and a compilation of 2834 reported cases (2018) Neuromuscul Disord., 28 (3), pp. 208-215
Finkel, R.S., Mercuri, E., Darras, B.T., Connolly, A.M., Kuntz, N.L., Kirschner, J., Nusinersen versus sham control in infantile-onset spinal muscular atrophy (2017) New Engl J Med., 377 (18), pp. 1723-1732
Pechmann, A., Konig, K., Bernert, G., Schachtrup, K., Schara, U., Schorling, D., SMArtCARE – a platform to collect real-life outcome data of patients with spinal muscular atrophy (2019) Orphanet J Rare Dis., 14 (1), p. 18
Aragon-Gawinska, K., Seferian, A.M., Daron, A., Gargaun, E., Vuillerot, C., Cances, C., Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study (2018) Neurology, 91 (14), pp. e1312-e13e8
Pane, M., Palermo, C., Messina, S., Sansone, V.A., Bruno, C., Catteruccia, M., Nusinersen in type 1 sma infants, children and young adults: preliminary results on motor function (2018) Neuromuscul Disord., 28 (7), pp. 582-585
Gidaro, T., Servais, L., Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps (2019) Dev Med Child Neurol., 61 (1), pp. 19-24
De Vivo, D., Bertini, E., Swoboda, K.J., Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study (2019) Neuromusc Disord, 29 (11), pp. 842-856
Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Single-dose gene-replacement therapy for spinal muscular atrophy (2017) N Engl Journal Med., 377 (18), pp. 1713-1722
Dabbous, O., Sproule, D., Feltner, D.E., Ogrinc, F.G., Menier, M., Droege, M., (2019), Event-Free survival and motor milestone achievement following AVXS-101 and nusinersen interventions contrasted to natural history for type I spinal muscular atrophy patients. AAN: S25: Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes
Servais, L., Baranello, G., Day, J.W., Deconinck, N., Mercuri, E.A.K., (2019), FIREFISH part 1: survival, ventilation and swallowing ability in infants with type 1 SMA receiving Risdiplam (RG7916). AAN: S25: Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes
Dangouloff, T., Servais, L., Clinical evidence supporting early treatment in SMA (2019) Ther Clin Risk Manag., 15, pp. 1153-1161
FDA, https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease, FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality: 05/24/2019
2019[Available from:
Wilson, J.M.G., Jungner, G., Principles and practice of screening for disease (1968) Public health paper, 34. , World Health Organization
Serra-Juhe, C., Tizzano, E.F., Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors (2019) Eur J Human Genet., 27 (12), pp. 1774-1782
Kraszewski, J.N., Kay, D.M., Stevens, C.F., Koval, C., Haser, B., Ortiz, V., Pilot study of population-based newborn screening for spinal muscular atrophy in new york state (2018) Genet Med., 20 (6), pp. 608-613
Boemer, F., Caberg, J.H., Dideberg, V., Dardenne, D., Bours, V., Hiligsmann, M., Newborn screening for SMA in Southern Belgium (2019) Neuromuscul Disord., 29 (5), pp. 343-349
Prior, T.W., Krainer, A.R., Hua, Y., Swoboda, K.J., Snyder, P.C., Bridgeman, S.J., A positive modifier of spinal muscular atrophy in the SMN2 gene (2009) Am J Hum Genet., 85 (3), pp. 408-413
Ruhno, C., McGovern, V.L., Avenarius, M.R., Snyder, P.J., Prior, T.W., Nery, F.C., Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype (2019) Hum Genet., 138 (3), pp. 241-256
Bernal, S., Alias, L., Barcelo, M.J., Also-Rallo, E., Martinez-Hernandez, R., Gamez, J., The c.859G>C variant in the SMN2 gene is associated with types II and III sma and originates from a common ancestor (2010) J Med Genet., 47 (9), pp. 640-642
Schorling, D.C., Becker, J., Pechmann, A., Langer, T., Wirth, B., Kirschner, J., Discrepancy in redetermination of SMN2 copy numbers in children with SMA (2019) Neurology, 93 (6), pp. 267-269
Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T.F., Wirth, B., Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy (2002) Am J Hum Genet., 70 (2), pp. 358-368
Yuan, A., Rao, M.V., Veeranna, Nixon, R.A., Neurofilaments and neurofilament proteins in health and disease (2017) Cold Spring Harb Perspect Biol, 9, p. a018309
Petzold, A., Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss (2005) J Neurol Sci., 233 (1-2), pp. 183-198
Mercuri, E., Darras, B.T., Chiriboga, C.A., Day, J.W., Campbell, C., Connolly, A.M., Nusinersen versus sham control in later-onset spinal muscular atrophy (2018) N Engl J Med., 378 (7), pp. 625-635
Darras, B.T., Chiriboga, C.A., Iannaccone, S.T., Swoboda, K.J., Montes, J., Mignon, L., Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies (2019) Neurology, 92 (21), pp. e2492-ee506
Human, N.F.-H., (2019), https://www.proteinsimple.com/documents/NF-H_Specification_Sheet_Rev_B.pdf, Simple plex assay for the detection of human neurofilament heavy (NF-H) in serum pEH, and cerebrospinal fluid (CSF) [ProteinSimple assay specification sheet]. Available at: Accessed 20 May
Darras, B.T., Crawford, T.O., Finkel, R.S., Mercuri, E., De Vivo, D.C., Oskoui, M., Neurofilament as a potential biomarker for spinal muscular atrophy (2019) Ann Clin Transl Neurol., 6 (5), pp. 932-944
Sumner, C.D.B., Muntoni, F., Crawford, T.O., Finkel, R.S., Mercuri, E., De Vivo, D.C., (2019), Association of phosphorylated neurofilament heavy chain (pNF-H) levels with motor function achievement in individuals with spinal muscular atrophy (SMA) treated with nusinersen. Proceedings of the AAN 2019 – Seventy-first Annual Meeting, May 4–10 Philadelphia, PA, USA
Olsson, B., Alberg, L., Cullen, N.C., Michael, E., Wahlgren, L., Kroksmark, A.K., NFL is a marker of treatment response in children with SMA treated with nusinersen (2019) J Neurol, 266, pp. 2129-2136
Winter, B., Guenther, R., Ludolph, A.C., Hermann, A., Otto, M., Wurster, C.D., Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen (2019) J Neurol Neurosurg Psychiatry, 90, pp. 1068-1069
Boemer, F., Caberg, J., Dideberg, V., Beckers, P., Marie, S., Marcelis, L., (S)un (M)ay (A)rise on SMA: l'espoir d'une région sans amyotrophie spinale [(S)un (M)ay (A)rise on SMA: the hope of a region without spinal muscular atrophy] (2019) Rev Med Liege, 74 (9), pp. 461-464
Czibere, L., Burggraf, S., Fleige, T., Gluck, B., Keitel, L.M., Landt, O., High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR (2019) Eur J Hum Genet., 90, pp. 1068-1069
Mokhtariye, A., Hagh-Nazari, L., Varasteh, A.-R., Keyfi, F., Diagnostic methods for Lysosomal storage disease (2019) Rep Biochem Mol Biol., 7 (2), pp. 119-128
Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic fibrosis foundation consensus report (2008) J Pediatr., 153 (2), pp. S4-S14
Tridello, G., Castellani, C., Meneghelli, I., Tamanini, A., Assael, B.M., Early diagnosis from newborn screening maximises survival in severe cystic fibrosis (2018) ERJ Open Res., 4 (2), pp. 00109-02017
Amato, A., Giordano, P.C., Screening and genetic diagnosis of hemoglobinopathies in southern and northern europe: two examples (2009) Mediterr J Hematol Infect Dis., 1 (1)
Abuli, A., Boada, M., Rodriguez-Santiago, B., Coroleu, B., Veiga, A., Armengol, L., NGS-Based assay for the identification of individuals carrying recessive genetic mutations in reproductive medicine (2016) Hum Mutat., 37 (6), pp. 516-523
Alias, L., Barcelo, M.J., Bernal, S., Martinez-Hernandez, R., Also-Rallo, E., Vazquez, C., Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene (2014) Clin Genet., 85 (5), pp. 470-475
Luo, M., Liu, L., Peter, I., Zhu, J., Scott, S.A., Zhao, G., An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy (2014) Genet Med., 16 (2), pp. 149-156
Alias, L., Bernal, S., Calucho, M., Martinez, E., March, F., Gallano, P., Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling (2018) Eur J Hum Genet., 26 (10), pp. 1554-1557
Jonsson, E., Banta, D., Treatments that fail to prove their worth. interview by Judy Jones (1999) BMJ, 319 (7220), p. 1293
Drummond, M., Jonsson, B., Rutten, F., The role of economic evaluation in the pricing and reimbursement of medicines (1997) Health Policy (New York), 40 (3), pp. 199-215
Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W., Methods for the economic evaluation of health care programmes (2015), 4th ed. Oxford: Oxford: Oxford University Press
Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold (2014) N Engl J Med., 371 (9), pp. 796-797
Pharmacoeconomic review report: Nusinersen (Spinraza): (Biogen Canada Inc): Indication: Treatment of patients with 5q SMA (2018), Canadian Agency for Drugs and Technologies in Health Ottawa (ON)
ICER, www.icer.org, SpinrazaⓇ and zolgensmaⓇ for spinal muscular atrophy: effectiveness and value. 2019. Institute for Clinical and Economic Review, 0403192019 i–iii
Zuluaga-Sanchez, S., Teynor, M., Knight, C., Thompson, R., Lundqvist, T., Ekelund, M., Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden (2019) PharmacoEcon., 37 (6), pp. 845-865
Garrison, L.P., Jackson, T., Paul, D., Kenston, M., Value-Based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold (2019) J Manag Care Spec Pharm, 27, pp. 795-799
Little, S.E., Janakiraman, V., Kaimal, A., Musci, T., Ecker, J., Caughey, A.B., The cost-effectiveness of prenatal screening for spinal muscular atrophy (2010) Am J Obstet Gynecol, 202 (3), pp. 253.e1-253.e7
Boardman, F.K., Young, P.J., Griffiths, F.E., Population screening for spinal muscular atrophy: a mixed methods study of the views of affected families (2017) Am J Med Genet A, 173 (2), pp. 421-434
Glascock, J., Sampson, J., Haidet-Phillips, A., Connolly, A., Darras, B., Day, J., Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening (2018) J Neuromuscul Dis, 5 (2), pp. 145-158
Darras, B.T., De Vivo, D.C., Precious SMA natural history data: a benchmark to measure future treatment successes (2018) Neurology, 91 (8), pp. 337-339
